Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2021-12-30 00:00:00 ET · period of report 2021-12-28 · accession 0000899243-21-050130 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2021-12-30 | 2021-12-28+ | BBIO | DANIELS RONALD J | Dir | P - Purchase | $13.49 | +22.1K | 11.7K | New | +$298.7K |
| 2021-12-30 | 2021-12-28 | BBIO | DANIELS RONALD J | Dir | S - Sale | $12.80 | -11.7K | 0 | -100% | -$150.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-30 | P | A | 10,402 | $14.34 | 10,402 | D | — | — | |
| 2 | Common | Common Stock | 2021-12-28 | P | A | 11,745 | $12.73 | 11,745 | D | — | — | (F1) The Reporting Person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of the purchase and sale of the Issuer's common stock on December 28, 2021 reported herein. The Reporting Person has agreed to voluntarily disgorge to the Issuer all short-swing profits realized by the Reporting Person from such transactions. (F2) Represents the weighted average sale price of the shares sold from $12.7275 to $12.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 and 3. |
| 3 | Common | Common Stock | 2021-12-28 | S | D | 11,745 | $12.80 | 0 | D | — | — | (F1) The Reporting Person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of the purchase and sale of the Issuer's common stock on December 28, 2021 reported herein. The Reporting Person has agreed to voluntarily disgorge to the Issuer all short-swing profits realized by the Reporting Person from such transactions. (F3) Represents the weighted average sale price of the shares sold from $12.79 to $12.82 per share. |